Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xilio Therapeutics (XLO) Return on Sales (2024 - 2025)

Xilio Therapeutics' Return on Sales history spans 2 years, with the latest figure at 0.1% for Q3 2025.

  • For Q3 2025, Return on Sales rose 642.0% year-over-year to 0.1%; the TTM value through Sep 2025 reached 1.38%, changed N/A, while the annual FY2024 figure was 9.55%, N/A changed from the prior year.
  • Return on Sales for Q3 2025 was 0.1% at Xilio Therapeutics, up from 1.78% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.1% in Q3 2025 and bottomed at 7.91% in Q4 2024.